Movement Alert｜GENSCRIPT BIO Rises 5.47% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% Year-over-Year Boosting Sentiment

Market Focus

07/31

On July 31, GENSCRIPT BIO rose 5.47% in regular trading, trading at HK$18.29/share, with turnover of HK$292 million. The stock's gain was driven by strong quarterly sales data from its associate company Legend Biotech's flagship CAR-T therapy CARVYKTI.

According to a company filing, Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately $657 million in the quarter ended June 30, representing a nearly 50% increase year-over-year and extending its robust growth trajectory. The sales figure was provided by collaboration partner Janssen Biotech under their cooperation and license agreement originally signed in December 2017. Neither Legend Biotech nor GENSCRIPT BIO independently verified the accuracy of the figure.

Beyond the commercial momentum of CARVYKTI, GENSCRIPT BIO's pipeline also showed progress, with Legend Biotech's potentially first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy LB2501 achieving clinical proof-of-concept in relapsed/refractory B-cell non-Hodgkin lymphoma patients in June, demonstrating dose-dependent CAR-T cell expansion without lymphodepletion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1174279530"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174279530\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174279530?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 13:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174279530","market":"hk","top_or_hot":-1,"title":"Movement Alert｜GENSCRIPT BIO Rises 5.47% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% Year-over-Year Boosting Sentiment","media":"Market Focus","content":"<p><p>On July 31, GENSCRIPT BIO rose 5.47% in regular trading, trading at HK$18.29/share, with turnover of HK$292 million. The stock's gain was driven by strong quarterly sales data from its associate company Legend Biotech's flagship CAR-T therapy CARVYKTI.</p><p>According to a company filing, Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately $657 million in the quarter ended June 30, representing a nearly 50% increase year-over-year and extending its robust growth trajectory. The sales figure was provided by collaboration partner Janssen Biotech under their cooperation and license agreement originally signed in December 2017. Neither Legend Biotech nor GENSCRIPT BIO independently verified the accuracy of the figure.</p><p>Beyond the commercial momentum of CARVYKTI, GENSCRIPT BIO's pipeline also showed progress, with Legend Biotech's potentially first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy LB2501 achieving clinical proof-of-concept in relapsed/refractory B-cell non-Hodgkin lymphoma patients in June, demonstrating dose-dependent CAR-T cell expansion without lymphodepletion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENSCRIPT BIO Rises 5.47% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% Year-over-Year Boosting Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENSCRIPT BIO Rises 5.47% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% Year-over-Year Boosting Sentiment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-07-31 13:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On July 31, GENSCRIPT BIO rose 5.47% in regular trading, trading at HK$18.29/share, with turnover of HK$292 million. The stock's gain was driven by strong quarterly sales data from its associate company Legend Biotech's flagship CAR-T therapy CARVYKTI.</p><p>According to a company filing, Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately $657 million in the quarter ended June 30, representing a nearly 50% increase year-over-year and extending its robust growth trajectory. The sales figure was provided by collaboration partner Janssen Biotech under their cooperation and license agreement originally signed in December 2017. Neither Legend Biotech nor GENSCRIPT BIO independently verified the accuracy of the figure.</p><p>Beyond the commercial momentum of CARVYKTI, GENSCRIPT BIO's pipeline also showed progress, with Legend Biotech's potentially first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy LB2501 achieving clinical proof-of-concept in relapsed/refractory B-cell non-Hodgkin lymphoma patients in June, demonstrating dose-dependent CAR-T cell expansion without lymphodepletion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1174279530","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174279530","pubTimestamp":1785474233,"columns":[{"name":"行業數據","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, GENSCRIPT BIO rose 5.47% in regular trading, trading at HK$18.29/share, with turnover of HK$292 million. The stock's gain was driven by strong quarterly sales data from its associate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势提醒|金斯瑞生物常规交易上涨5.47%，CARVYKTI第二季度销售额同比飙升近50%，提振市场情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On July 31, GENSCRIPT BIO rose 5.47% in regular trading, trading at HK$18.29/share, with turnover of HK$292 million. The stock's gain was driven by strong quarterly sales data from its associate company Legend Biotech's flagship CAR-T therapy CARVYKTI.According to a company filing, Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately $657 million in the quarter ended June 30, representing a nearly 50% increase year-over-year and extending its robust growth trajectory. The sales figure was provided by collaboration partner Janssen Biotech under their cooperation and license agreement originally signed in December 2017. Neither Legend Biotech nor GENSCRIPT BIO independently verified the accuracy of the figure.Beyond the commercial momentum of CARVYKTI, GENSCRIPT BIO's pipeline also showed progress, with Legend Biotech's potentially first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy LB2501 achieving clinical proof-of-concept in relapsed/refractory B-cell non-Hodgkin lymphoma patients in June, demonstrating dose-dependent CAR-T cell expansion without lymphodepletion.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}